SALVAGE THERAPY FOR MULTI DRUG RESISTANT TUBERCULOSIS

多重耐药结核病的挽救治疗

• 批准号: 6305592
• 负责人: Henry F HENRY CHAMBERS
• 金额: $ 0.06万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6305592
• 关键词: aminoglycoside antibiotics; antiinfective agents; antitubercular agents; beta lactam antibiotic; clinical research; clinical trials; combination chemotherapy; drug screening /evaluation; human subject; human therapy evaluation; macrolide antibiotics; microorganism disease chemotherapy; multidrug resistance; respiratory disorder chemotherapy; rifamycins; tuberculosis

This is a prospective, open-label study testing the efficacy of beta-lactam antibiotics, fluroquinolones, aminoglycosides, rifamycin derivatives, and possibly macrolides for salvage therapy for patients with multi-drug resistant tuberculosis.

这是一项前瞻性、开放性研究，测试 β-内酰胺类抗生素、氟喹诺酮类药物、氨基糖苷类药物、利福霉素衍生物以及可能的大环内酯类药物对多重耐药结核病患者挽救治疗的疗效。